文献速递支持与姑息治疗泌尿男性生殖肿瘤

瘤内poly-ICLC联合树突细胞疫苗与放疗治疗晚期癌症的I期研究

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
PubMed 文献 · Ann Oncol · 2018-01-01

这项两队列试点I期研究纳入15例晚期癌症患者,给予瘤内注射dsRNA类似物Hiltonol、自体肿瘤裂解物负载树突细胞疫苗及环磷酰胺预处理,其中6例接受SABR。联合治疗安全耐受,9例达SD,1例去势抵抗性前列腺癌患者出现显著混合性远隔效应,未见客观缓解。

要点

  • 联合方案安全耐受,未观察到客观缓解,9例达稳定疾病。
  • 6例放疗队列中5例达SD,1例前列腺癌患者出现混合性远隔效应。
  • 瘤内Hiltonol升高PBMC中IFN-β/IFN-α mRNA,DC疫苗升高血清IL-12和IL-1β。

核心结论

  • 该放射免疫联合策略模拟肿瘤组织内病毒感染,联合树突细胞疫苗和SABR,安全并显示免疫相关活性和初步临床疗效迹象。

研究设计与样本

  • 两队列试点I期研究,纳入15例晚期癌症患者。
  • 患者接受两个4周周期,每周期每日皮内注射载有自体肿瘤裂解物并经poly-ICLC、TNF-α和IFN-α成熟24小时的单核细胞来源树突细胞,共4次。
  • 每周期第+8和+10天,瘤内影像引导注射0.25 mg dsRNA类似物Hiltonol。
  • 环磷酰胺600 mg/m2于治疗前1周给药。
  • 6例患者对选定肿瘤病灶(包括注射Hiltonol的病灶)接受立体定向消融放疗(SABR)。

主要发现

  • 联合治疗安全且耐受良好。
  • 1例经重度预处理去势抵抗性前列腺癌患者对SABR+免疫治疗出现显著混合性远隔效应。
  • 未观察到客观缓解,9例患者达稳定疾病(SD),其中5例来自6例放疗队列。
  • 瘤内Hiltonol升高循环PBMC中IFN-β和IFN-α mRNA。
  • DC疫苗升高血清IL-12和IL-1β浓度,尤其在达SD的患者中。

关键数值与推荐

  • 瘤内Hiltonol剂量为0.25 mg,每周期第+8和+10天给药。
  • 环磷酰胺剂量为600 mg/m2,治疗前1周给药。
  • 树突细胞每日皮内注射,每周期4次,共两个4周周期。
  • 通过RT-PCR监测25个免疫相关基因在循环PBMC中的表达。

临床怎么用

  • 该联合方案在晚期癌症中安全耐受,可作为后续研究的基础。
  • 稳定疾病和免疫相关活性提示需进一步评估疗效,尤其结合SABR。
  • 治疗中可监测PBMC干扰素mRNA和血清细胞因子作为免疫活性指标。

局限性

  • 为试点I期研究,样本量小(15例),未设对照组。
  • 未观察到客观缓解,疗效信号有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and repeated vaccinations with tumor-lysate loaded dendritic cells shows efficacy against colon cancer mouse models. In the context of immunotherapy, radiotherapy can exert beneficial abscopal effects. PATIENTS AND METHODS: In this two-cohort pilot phase I study, 15 advanced cancer patients received two 4-week cycles of four intradermal daily doses of monocyte-derived dendritic cells preloaded with autologous tumor lysate and matured for 24 h with poly-ICLC (Hiltonol), TNF-α and IFN-α. On days +8 and +10 of each cycle, patients received intratumoral image-guided 0.25 mg injections of the dsRNA-analogue Hiltonol. Cyclophosphamide 600 mg/m2 was administered 1 week before. Six patients received stereotactic ablative radiotherapy (SABR) on selected tumor lesions, including those injected with Hiltonol. Expression of 25 immune-relevant genes was sequentially monitored by RT-PCR on circulating peripheral blood mononuclear cell (PBMCs) and serum concentrations of a cytokine panel were sequentially determined before and during treatment. Pre- and post-treatment PBMC from patients achieving durable stable disease (SD) were studied by IFNγ ELISPOT-assays responding to tumor-lysate loaded DC and by TCRβ sequencing. RESULTS: Combined treatment was, safe and well tolerated. One heavily pretreated castration-resistant prostate cancer patient experienced a remarkable mixed abscopal response to SABR+ immunotherapy. No objective responses were observed, while nine patients presented SD (five of them in the six-patient radiotherapy cohort). Intratumoral Hiltonol increased IFN-β and IFN-α mRNA in circulating PBMC. DC vaccination increased serum IL-12 and IL-1β concentrations, especially in patients presenting SD. IFNγ-ELISPOT reactivity to tumor lysates was observed in two patients experiencing durable SD. CONCLUSIONS: This radio-immunotherapy combination strategy, aimed at resembling viral infection in tumor tissue in combination with a dendritic-cell vaccine and SABR, is safe and shows immune-associated activity and signs of preliminary clinical efficacy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol. 2018. PMID: 29554212. doi:10.1093/annonc/mdy089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。